Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib

Kosuke Masutani, Kiichiro Fujisaki, Hiroto Maeda, Jiro Toyonaga, Ichiro Inoshima, Koichi Takayama, Ritsuko Katafuchi, Hideki Hirakata, Kazuhiko Tsuruya, Mitsuo Iida

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A 52-year-old Japanese female was admitted to our hospital for microhematuria, proteinuria and progressive renal dysfunction. Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day). Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors. After confirmation of the partial remission state, we performed percutaneous renal biopsy. Glomeruli showed mild to moderate mesangial proliferation, segmental endocapillary proliferation and occasional fibrocellular crescent formation. In addition, severe interstitial fibrosis and tubular atrophy relative to the degree of glomerular sclerosis were noted. Immunofluorescence microscopy showed predominant IgA deposition in the mesangial area. Electron microscopy revealed subepithelial and paramesangial electron-dense deposits. In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic. Sixteen months later, she continued to have proteinuria and microhematuria, and the severity of renal dysfunction was still the same. However, the lung cancer started to increase in size. This is quite an unusual case presenting histologically with tubulointerstitial nephritis and IgA nephropathy in a patient on long-term treatment with gefitinib.

Original languageEnglish
Pages (from-to)398-402
Number of pages5
JournalClinical and Experimental Nephrology
Volume12
Issue number5
DOIs
Publication statusPublished - Oct 1 2008

Fingerprint

Interstitial Nephritis
Immunoglobulin A
Lung Neoplasms
Kidney
Proteinuria
Sclerosis
Immunosuppressive Agents
Ambulatory Care Facilities
Fluorescence Microscopy
Atrophy
Neoplasms
Electron Microscopy
Fibrosis
Therapeutics
Electrons
Neoplasm Metastasis
Biopsy
Bone and Bones
Lung
Brain

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. / Masutani, Kosuke; Fujisaki, Kiichiro; Maeda, Hiroto; Toyonaga, Jiro; Inoshima, Ichiro; Takayama, Koichi; Katafuchi, Ritsuko; Hirakata, Hideki; Tsuruya, Kazuhiko; Iida, Mitsuo.

In: Clinical and Experimental Nephrology, Vol. 12, No. 5, 01.10.2008, p. 398-402.

Research output: Contribution to journalArticle

Masutani, K, Fujisaki, K, Maeda, H, Toyonaga, J, Inoshima, I, Takayama, K, Katafuchi, R, Hirakata, H, Tsuruya, K & Iida, M 2008, 'Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib', Clinical and Experimental Nephrology, vol. 12, no. 5, pp. 398-402. https://doi.org/10.1007/s10157-008-0066-1
Masutani, Kosuke ; Fujisaki, Kiichiro ; Maeda, Hiroto ; Toyonaga, Jiro ; Inoshima, Ichiro ; Takayama, Koichi ; Katafuchi, Ritsuko ; Hirakata, Hideki ; Tsuruya, Kazuhiko ; Iida, Mitsuo. / Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. In: Clinical and Experimental Nephrology. 2008 ; Vol. 12, No. 5. pp. 398-402.
@article{4b17421393594860b0e5e9fbc4eec5c6,
title = "Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib",
abstract = "A 52-year-old Japanese female was admitted to our hospital for microhematuria, proteinuria and progressive renal dysfunction. Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day). Treatment for 6 months induced partial response with 30{\%} regression of the primary lung tumor, and resolution of metastatic tumors. After confirmation of the partial remission state, we performed percutaneous renal biopsy. Glomeruli showed mild to moderate mesangial proliferation, segmental endocapillary proliferation and occasional fibrocellular crescent formation. In addition, severe interstitial fibrosis and tubular atrophy relative to the degree of glomerular sclerosis were noted. Immunofluorescence microscopy showed predominant IgA deposition in the mesangial area. Electron microscopy revealed subepithelial and paramesangial electron-dense deposits. In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic. Sixteen months later, she continued to have proteinuria and microhematuria, and the severity of renal dysfunction was still the same. However, the lung cancer started to increase in size. This is quite an unusual case presenting histologically with tubulointerstitial nephritis and IgA nephropathy in a patient on long-term treatment with gefitinib.",
author = "Kosuke Masutani and Kiichiro Fujisaki and Hiroto Maeda and Jiro Toyonaga and Ichiro Inoshima and Koichi Takayama and Ritsuko Katafuchi and Hideki Hirakata and Kazuhiko Tsuruya and Mitsuo Iida",
year = "2008",
month = "10",
day = "1",
doi = "10.1007/s10157-008-0066-1",
language = "English",
volume = "12",
pages = "398--402",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib

AU - Masutani, Kosuke

AU - Fujisaki, Kiichiro

AU - Maeda, Hiroto

AU - Toyonaga, Jiro

AU - Inoshima, Ichiro

AU - Takayama, Koichi

AU - Katafuchi, Ritsuko

AU - Hirakata, Hideki

AU - Tsuruya, Kazuhiko

AU - Iida, Mitsuo

PY - 2008/10/1

Y1 - 2008/10/1

N2 - A 52-year-old Japanese female was admitted to our hospital for microhematuria, proteinuria and progressive renal dysfunction. Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day). Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors. After confirmation of the partial remission state, we performed percutaneous renal biopsy. Glomeruli showed mild to moderate mesangial proliferation, segmental endocapillary proliferation and occasional fibrocellular crescent formation. In addition, severe interstitial fibrosis and tubular atrophy relative to the degree of glomerular sclerosis were noted. Immunofluorescence microscopy showed predominant IgA deposition in the mesangial area. Electron microscopy revealed subepithelial and paramesangial electron-dense deposits. In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic. Sixteen months later, she continued to have proteinuria and microhematuria, and the severity of renal dysfunction was still the same. However, the lung cancer started to increase in size. This is quite an unusual case presenting histologically with tubulointerstitial nephritis and IgA nephropathy in a patient on long-term treatment with gefitinib.

AB - A 52-year-old Japanese female was admitted to our hospital for microhematuria, proteinuria and progressive renal dysfunction. Two years prior to admission, she was diagnosed with lung adenocarcinoma and multiple bone and brain metastases, and was treated with gefitinib (250 mg/day). Treatment for 6 months induced partial response with 30% regression of the primary lung tumor, and resolution of metastatic tumors. After confirmation of the partial remission state, we performed percutaneous renal biopsy. Glomeruli showed mild to moderate mesangial proliferation, segmental endocapillary proliferation and occasional fibrocellular crescent formation. In addition, severe interstitial fibrosis and tubular atrophy relative to the degree of glomerular sclerosis were noted. Immunofluorescence microscopy showed predominant IgA deposition in the mesangial area. Electron microscopy revealed subepithelial and paramesangial electron-dense deposits. In consideration of the prognosis of lung cancer and complication of immunosuppressive treatment, we continued gefitinib only and closely followed-up the clinical course in the outpatient clinic. Sixteen months later, she continued to have proteinuria and microhematuria, and the severity of renal dysfunction was still the same. However, the lung cancer started to increase in size. This is quite an unusual case presenting histologically with tubulointerstitial nephritis and IgA nephropathy in a patient on long-term treatment with gefitinib.

UR - http://www.scopus.com/inward/record.url?scp=51849095868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849095868&partnerID=8YFLogxK

U2 - 10.1007/s10157-008-0066-1

DO - 10.1007/s10157-008-0066-1

M3 - Article

VL - 12

SP - 398

EP - 402

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 5

ER -